Landry Robert E's Form 4 filing
Regeneron Pharmaceuticals, Inc. (REGN) · filed Dec 2, 2022
- Accession no.
- 0001883850-22-000102
- Filed
- Dec 2, 2022
- Trade date
- Dec 1-2, 2022
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 5 non-derivative transactions and 1 derivative transaction. Open-market sales total $461.6K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Landry Robert ECIK 0001585160 | Officer (EVP Finance CFO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 1, 2022 | Common Stock | MOption exerciseAcquired | +2,500 | $381.92 | +$954,800 | 31,244 | Direct | |
| Dec 1, 2022 | Common Stock | FTax withholdingDisposed | −1,890 | $760.35 | −$1,437,061.5 | 29,354 | Direct | |
| Dec 2, 2022 | Common Stock | SSaleDisposed | −582 | $756.50 | −$440,283 | 28,772 | Direct | |
| Dec 2, 2022 | Common Stock | SSaleDisposed | −16 | $759.90 | −$12,158.4 | 28,756 | Direct | |
| Dec 2, 2022 | Common Stock | SSaleDisposed | −12 | $760.19 | −$9,122.28 | 28,744 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 1, 2022 | Common Stock | MOption exerciseDisposed | −2,500 | $0.00 | $0 | 6,800 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.